Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Danish Headache Center
Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced.
The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
diagnosis of migraine, according to IHS criteria
weight between 50 - 100 kilograms
women in fertile age must not be pregnant and must use adequate contraception
You may not be if
migraine more than 5 days per month in average over the past year
any primary headache other than migraine, apart from tension-type headache which must be less than 5 days per month
headache \< 48 hours before experimental day
migraine \< 72 hours before each experimental day
daily / frequent use of any medication apart from contraceptive medication
use of any drug less than 5 times the half-life of the drug at the time of the experiment
women who are pregnant or breast-feeding at the time of the experiment
anamnestic or clinical signs of hypertension (systolic blood pressure \> 150 mmHg and/or
